Protocol Ledger

NCT07406633 · Phase II · RECRUITING

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

Interventional Phase II clinical trial protocol NCT07406633 sponsored by Kumquat Biosciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-23 Enrollment: 46 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07406633
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)46 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07406633
Protocol FieldVerified Registry Value
NCT IdentifierNCT07406633
Consolidated Lead SponsorKumquat Biosciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment46 participants (ESTIMATED)
Registered Start Date2026-06-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI